http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2841745-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d829f463baf07a56b9778d3ded43b798 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7004 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 |
| filingDate | 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bbc772532db2ce3a17bf7abeb60e459 |
| publicationDate | 2021-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2841745-T3 |
| titleOfInvention | Treatment of glycosylation deficiency diseases |
| abstract | A uridine prodrug for use in treating a genetic disorder of glycosylation in a subject, wherein said treatment comprises administering the uridine prodrug to the subject in an amount sufficient to raise the subject's plasma uridine to a higher level than 30 micromolar; wherein the uridine prodrug is uridine triacetate; and wherein: (a) said treatment comprises administering the uridine prodrug in one or more doses of 0.5 to 5 grams of the uridine prodrug per square meter of body surface area; wherein optionally the uridine prodrug dose is 1.5 to 3 grams per meter of body surface area; (b) the uridine prodrug is formulated for administration in one or more doses of 0.5 to 5 grams of the uridine prodrug per square meter of body surface area; wherein optionally the uridine prodrug dose is 1.5 to 3 grams per meter of body surface area; or (c) said treatment comprises the administration of the uridine prodrug in one or more doses of 2 to 10 grams. |
| priorityDate | 2014-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 139.